Sector News

Pharma-backed Outpost nabs Mitsubishi, Pfizer exec Ian Mills

December 5, 2017
Life sciences

The pharma-biotech executive jumps show no sign of abating as a former Pfizer vet joins the ranks of startup Outpost Medicine as its R&D trials lead.

Ian Mills, M.D., becomes its new chief medical officer, coming from his role as head of clinical development at Mitsubishi Tanabe Pharma Europe; before this, he was a long-serving Pfizer vet serving across several research posts, with a focus on urology.

Outpost, with bases in Indianapolis and London, launched just last year and has since raised $61 million in a series A from the likes of Frazier Healthcare Partners, Adams Street Partners, Novo Holdings, Vivo Capital and Takeda Venture.

When it launched, Takeda gave out an exclusive license to the early-stage biotech for a clinical-stage product candidate in testing for stress urinary incontinence.

“Ian will be an outstanding addition to our leadership team, and we are very pleased to welcome him to Outpost,” said Scott Byrd, CEO of Outpost and formerly of Acacia Pharma and Lilly, in a release. “His extensive global drug development experience, including successfully guiding two pharmaceutical products to FDA approval for urology indications, will be pivotal to building our capabilities and leading the development of our lead product candidate, OP-687, for the treatment of overactive bladder and irritable bowel syndrome.”

By Ben Adams

Source: Fierce Biotech

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).